<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIOVAN HCT- valsartan and hydrochlorothiazide tablet, film coated </strong><br>Dispensing Solutions, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use</span><span class="Bold"></span><span class="Bold">Diovan</span><span class="Bold">HCT</span><span class="Bold"></span><span class="Bold">safely and effectively. </span><span class="Bold">See full prescribing information for</span><span class="Italics"></span><span class="Bold">Diovan</span><span class="Bold">HCT.</span><br><span class="Bold">Diovan HCT<span class="Sup">®</span> (valsartan and hydrochlorothiazide USP) Tablets</span><br><span class="Bold">Initial U.S. Approval: 1998</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">When pregnancy is detected, discontinue Diovan HCT as soon as possible. (<a href="#s5p1">5.1</a>)</span></li>
<li><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#s5p1">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Boxed Warning:  Fetal Toxicity		     
01/2012 </p>
<p class="Highlighta">Indications and Usage:  Benefits of lowering blood pressure (<a href="#s1">1</a>)		     
12/2011 </p>
<p class="Highlighta">Contraindications:  Dual RAS Blockade in Diabetics (<a href="#s4">4</a>)		     
10/2012 </p>
<p class="Highlighta">Warnings and Precautions:  Fetal Toxicity (<a href="#s5p1">5.1</a>)		     
01/2012 </p>
<p class="Highlighta">Warnings and Precautions: Potassium Abnormalities (<a href="#s5p7">5.7</a>)		     
07/2012 </p>
<p class="Highlighta">Drug Interactions:  Dual Blockade of the Renin-Angiotensin 
System (<a href="#s7">7</a>)		     
10/2012 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">When pregnancy is detected, discontinue Diovan HCT as soon as possible. (<a href="#s5p1">5.1</a>)</span></li>
<li><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#s5p1">5.1</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Diovan HCT is the combination tablet of valsartan (Diovan), an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ), a diuretic. Diovan HCT is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure: </p>
<ul class="Disc">
<li>In patients not adequately controlled with monotherapy (<a href="#s1">1</a>)</li>
<li>As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (<a href="#s1">1</a>)</li>
</ul>
<p class="Highlighta"><br>Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>.  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Dose once daily. Titrate as needed to a maximum dose of 320/25mg  (<a href="#s2">2</a>)<br>
</li>
<li>May be used as add-on/switch therapy for patients not adequately controlled on any of the components (valsartan or HCTZ) (<a href="#s2">2</a>)<br>
</li>
<li>May be substituted for titrated components (<a href="#s2p3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets (valsartan/HCTZ mg): 80/12.5, 160/12.5, 160/25, 320/12.5, 320/25 (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"> <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any sulfonamide-derived drugs or any component; Do not coadminister aliskiren with Diovan HCT in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (<a href="#s4">4</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:  Correct <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> prior to initiation  (<a href="#s5p2">5.2</a>)<br>
</li>
<li>Observe for signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>  (<a href="#s5p9">5.9</a>)<br>
</li>
<li>Monitor renal function and potassium in susceptible patients  (<a href="#s5p3">5.3</a>, <a href="#s5p7">5.7</a>) <br>
</li>
<li>Exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>  (<a href="#s5p5">5.5</a>)<br>
</li>
<li>Acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#s5p8">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common reasons for discontinuation of therapy with Diovan HCT were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The only adverse experience that occurred in ≥2% of patients treated with Diovan HCT and at a higher incidence than placebo was <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (2.4% vs. 1.9%). (<a href="#s6p1">6.1</a>) </p>
<span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (<a href="#s7">7</a>)<br>
</li>
<li>Cholestyramine and colestipol: Reduced absorption of thiazides (<a href="#s12p3">12.3</a>)<br>
</li>
<li>Lithium: Diuretics increase risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.  Monitor serum lithium concentrations during concurrent use. (<a href="#s7">7</a>)<br>
</li>
<li>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): May increase risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Can reduce diuretic, natriuretic and antihypertensive effects of diuretics. (<a href="#s7">7</a>)<br>
</li>
<li>Dual inhibition of the renin-angiotensin system:  Increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#s7">7</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Nursing Mothers: </span>Nursing or drug should be discontinued (<a href="#s8p3">8.3</a>) </p>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 10/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: FETAL TOXICITY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1     INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2     DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc">
2.1     General Considerations
</a></h2>
<h2><a href="#section-2.2" class="toc">
2.2     Add-On Therapy
</a></h2>
<h2><a href="#section-2.3" class="toc">
2.3     Replacement Therapy
</a></h2>
<h2><a href="#section-2.4" class="toc">
2.4     Initial Therapy
</a></h2>
<h2><a href="#section-2.5" class="toc">
2.5     Use with Other Antihypertensive Drugs
</a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3     DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4     CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5     WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc">
5.1     Fetal Toxicity
</a></h2>
<h2><a href="#section-5.2" class="toc">
5.2     <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- and/or Salt-Depleted Patients
</a></h2>
<h2><a href="#section-5.3" class="toc">
5.3     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">
5.4     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">
5.5     <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">
5.6     Lithium Interaction
</a></h2>
<h2><a href="#section-5.7" class="toc">
5.7     Potassium Abnormalities
</a></h2>
<h2><a href="#section-5.8" class="toc">
5.8     Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">
5.9     Metabolic Disturbances
</a></h2>
<h1><a href="#section-6" class="toc">
6     ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">
6.1     Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">
6.2     Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7     DRUG INTERACTIONS</span></a></h1>
<h1><a href="#section-8" class="toc"><span class="Bold">8     USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc">
8.1     Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">
8.3     Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">
8.4     Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">
8.5     Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">
8.6     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">
8.7     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10     OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11     DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12     CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc">
12.1     Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">
12.2     Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">
12.3     Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13     NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc">
13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h2><a href="#section-12.2" class="toc">
13.3     Developmental Toxicity Studies
</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14     CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc">
14.1     <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</a></h2>
<h2><a href="#section-13.2" class="toc">
14.2     Initial Therapy - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</a></h2>
<h1><a href="#section-14" class="toc">
16     HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">
17     PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: FETAL TOXICITY</span></h1>
<ul class="Disc">
<li><span class="Bold">When pregnancy is detected, discontinue Diovan HCT as soon as possible. (5.1) </span></li>
<li><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (5.1)</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1     INDICATIONS AND USAGE</span></h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality have also been seen regularly. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy. </span></p>
<p><span class="Italics">Add-On Therapy</span></p>
<p>Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy.</p>
<p><span class="Italics">Replacement Therapy</span></p>
<p>Diovan HCT may be substituted for the titrated components.</p>
<p><span class="Italics">Initial Therapy</span></p>
<p>Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals.</p>
<p>The choice of Diovan HCT as initial therapy for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should be based on an assessment of potential benefits and risks.</p>
<p>Patients with stage 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> are at a relatively high risk for cardiovascular events (such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk.</p>
<p>Data from the high dose multifactorial trial [<span class="Italics">see Clinical Studies</span> (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.</p>
<table>
<colgroup>
<col width="319">
<col width="319">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td>
<img alt="Figure 1: Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=diovan-hct-01.jpg"><br><span class="Bold">Figure 1</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week </span><span class="Bold">8</span>
</td>
<td>
<img alt="Figure 2: Probability of Achieving Diastolic Blood Pressure &lt;90 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=diovan-hct-02.jpg"><br><span class="Bold">Figure 2</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Diastolic Blood Pressure</span><span class="Bold">&lt;90 mmHg at Week </span><span class="Bold">8</span>
</td>
</tr>
<tr class="Last">
<td>
<img alt="Figure 3: Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=diovan-hct-03.jpg"><br><span class="Bold">Figure 3</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week </span><span class="Bold">8</span>
</td>
<td>
<img alt="Figure 4: Probability of Achieving Diastolic Blood Pressure &lt;80 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=diovan-hct-04.jpg"><br><span class="Bold">Figure 4</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Diastolic Blood Pressure</span><span class="Bold">&lt;80 mmHg at Week </span><span class="Bold">8</span>
</td>
</tr>
</tbody>
</table>
<p>For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of &lt;140 mmHg (systolic) and 60% likelihood of achieving &lt;90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2     DOSAGE AND ADMINISTRATION</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p1"></a><a name="section-2.1"></a><p></p>
<h2>
2.1     General Considerations
</h2>
<p class="First">The usual starting dose is Diovan HCT 160/12.5 mg once daily.  The dosage can be increased after 1 to 2 weeks of therapy to a maximum of one 320/25 tablet once daily as needed to control blood pressure  [<span class="Italics">see Clinical Studies (14.2)</span>].  Maximum antihypertensive effects are attained within 2 to 4 weeks after a change in dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p2"></a><a name="section-2.2"></a><p></p>
<h2>
2.2     Add-On Therapy
</h2>
<p class="First">A patient whose blood pressure is not adequately controlled with valsartan (or another ARB) alone or hydrochlorothiazide alone may be switched to combination therapy with Diovan HCT. </p>
<p>A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Diovan HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. The clinical response to Diovan HCT should be subsequently evaluated and if blood pressure remains uncontrolled after 3 to 4 weeks of therapy, the dose may be titrated up to a maximum of 320/25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p3"></a><a name="section-2.3"></a><p></p>
<h2>
2.3     Replacement Therapy
</h2>
<p class="First">Diovan HCT may be substituted for the titrated components.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p4"></a><a name="section-2.4"></a><p></p>
<h2>
2.4     Initial Therapy
</h2>
<p class="First">Diovan HCT is not recommended as initial therapy in patients with intravascular <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> [<span class="Italics">see Warnings and Precautions (5.2)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p5"></a><a name="section-2.5"></a><p></p>
<h2>
2.5     Use with Other Antihypertensive Drugs
</h2>
<p class="First">Diovan HCT may be administered with other antihypertensive agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3     DOSAGE FORMS AND STRENGTHS</span></h1>
<p class="First">80/12.5 mg tablets, imprinted CG/HGH (Side 1/Side 2)</p>
<p>160/12.5 mg tablets, imprinted CG/HHH</p>
<p>160/25 mg tablets, imprinted NVR/HXH</p>
<p>320/12.5 mg tablets, imprinted NVR/HIL</p>
<p>320/25 mg tablets, imprinted NVR/CTI</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4     CONTRAINDICATIONS</span></h1>
<p class="First">Diovan HCT (valsartan and hydrochlorothiazide, USP) is contraindicated in patients who are hypersensitive to any component of this product.</p>
<p>Because of the hydrochlorothiazide component, this product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other sulfonamide-derived drugs.</p>
<p style="border-left:1px solid;"><span class="XmChange">Do not coadminister aliskiren with Diovan HCT in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> [<span class="Italics">see Drug Interactions (7)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5     WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p1"></a><a name="section-5.1"></a><p></p>
<h2>
5.1     Fetal Toxicity
</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations.  Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue Diovan HCT as soon as possible [<span class="Italics">see Use in Specific Populations (8.1)</span>].</span></p>
<p>Intrauterine exposure to thiazide diuretics is associated with fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p2"></a><a name="section-5.2"></a><p></p>
<h2>
5.2     <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- and/or Salt-Depleted Patients
</h2>
<p class="First">Excessive reduction of blood pressure was rarely seen (0.7%) in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with Diovan HCT in controlled trials. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur. This condition should be corrected prior to administration of Diovan HCT, or the treatment should start under close medical supervision.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p3"></a><a name="section-5.3"></a><p></p>
<h2>
5.3     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</h2>
<p class="First">
Changes in renal function including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span>, <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>, severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>) may be at particular risk of developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> on Diovan HCT.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on Diovan HCT [<span class="Italics">see Drug Interactions (7)</span>].  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p4"></a><a name="section-5.4"></a><p></p>
<h2>
5.4     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span>
</h2>
<p class="First"><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p5"></a><a name="section-5.5"></a><p></p>
<h2>
5.5     <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span>
</h2>
<p class="First"><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p6"></a><a name="section-5.6"></a><p></p>
<h2>
5.6     Lithium Interaction
</h2>
<p class="First"><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Lithium generally should not be given with thiazides [<span class="Italics">see </span><span class="Italics">Drug Interactions</span><span class="Italics"> (7)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p7"></a><a name="section-5.7"></a><p></p>
<h2>
5.7     Potassium Abnormalities
</h2>
<p class="First"><span class="Bold">Valsartan – Hydrochlorothiazide</span><span class="Bold">: </span>In the controlled trials of various doses of Diovan HCT the incidence of hypertensive patients who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5 mEq/L) was 3.0%; the incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt;5.7 mEq/L) was 0.4%.</p>
<p>Hydrochlorothiazide can cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.  <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> can result in <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> which appears difficult to treat despite potassium repletion.  Drugs that inhibit the renin-angiotensin system can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.  Monitor serum electrolytes periodically. </p>
<p>If <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is accompanied by clinical signs (e.g. <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, or ECG alterations), Diovan HCT should be discontinued.  Correction of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and any coexisting <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> is recommended prior to the initiation of thiazides.</p>
<p style="border-left:1px solid;"><span class="XmChange">Some patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have developed increases in potassium with Diovan therapy.   These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction and/or discontinuation of the diuretic and/or Diovan may be required [<span class="Italics">see Adverse Reactions (6.1)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p8"></a><a name="section-5.8"></a><p></p>
<h2>
5.8     Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>
</h2>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation.  Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.  The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible.  Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled.  Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p9"></a><a name="section-5.9"></a><p></p>
<h2>
5.9     Metabolic Disturbances
</h2>
<p class="First"><span class="Bold Italics">Hydrochlorothiazide</span></p>
<p>Hydrochlorothiazide may alter glucose tolerance and raise serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides.</p>
<p>Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and precipitate <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> in susceptible patients.</p>
<p>Hydrochlorothiazide decreases urinary calcium excretion and may cause elevations of serum calcium. Monitor calcium levels in patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> receiving Diovan HCT.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>
6     ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p1"></a><a name="section-6.1"></a><p></p>
<h2>
6.1     Clinical Trials Experience
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>Diovan HCT (valsartan and hydrochlorothiazide, USP) has been evaluated for safety in more than 5700 patients, including over 990 treated for over 6 months, and over 370 for over 1 year. Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse reactions with Diovan HCT was comparable to placebo.</p>
<p>The overall frequency of adverse reactions was neither dose-related nor related to gender, age, or race. In controlled clinical trials, discontinuation of therapy due to side effects was required in 2.3% of valsartan-hydrochlorothiazide patients and 3.1% of placebo patients. The most common reasons for discontinuation of therapy with Diovan HCT were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>The only adverse reaction that occurred in controlled clinical trials in at least 2% of patients treated with Diovan HCT and at a higher incidence in valsartan-hydrochlorothiazide (n=4372) than placebo (n=262) patients was <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (2.4% vs. 1.9%).</p>
<p>Dose-related orthostatic effects were seen in fewer than 1% of patients. In individual trials, a dose-related increase in the incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was observed in patients treated with Diovan HCT.</p>
<p>Other adverse reactions that have been reported with valsartan-hydrochlorothiazide (&gt;0.2% of valsartan-hydrochlorothiazide patients in controlled clinical trials) without regard to causality, are listed below:</p>
<p><span class="Bold Italics">Cardiovascular</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold Italics">Ear and </span><span class="Bold Italics">L</span><span class="Bold Italics">abyrinth</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold Italics">Gastrointestinal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold Italics">General and </span><span class="Bold Italics">A</span><span class="Bold Italics">dministration </span><span class="Bold Italics">S</span><span class="Bold Italics">ite </span><span class="Bold Italics">C</span><span class="Bold Italics">onditions</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and </span><span class="Bold Italics">I</span><span class="Bold Italics">nfestations</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis acute</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<p><span class="Bold Italics">Investigations</span><span class="Bold Italics">: </span>Blood urea increased</p>
<p><span class="Bold Italics">Musculoskeletal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span></p>
<p><span class="Bold Italics">Nervous </span><span class="Bold Italics">S</span><span class="Bold Italics">ystem</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">Dizziness postural</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Bold Italics">Psychiatric</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p>
<p><span class="Bold Italics">Renal and </span><span class="Bold Italics">U</span><span class="Bold Italics">rinary</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Pollakiuria</span></p>
<p><span class="Bold Italics">Reproductive </span><span class="Bold Italics">S</span><span class="Bold Italics">ystem</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span></p>
<p><span class="Bold Italics">Respiratory, </span><span class="Bold Italics">T</span><span class="Bold Italics">horacic and </span><span class="Bold Italics">M</span><span class="Bold Italics">ediastinal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span></p>
<p><span class="Bold Italics">Skin and </span><span class="Bold Italics">S</span><span class="Bold Italics">ubcutaneous </span><span class="Bold Italics">T</span><span class="Bold Italics">issue</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold Italics">Vascular</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
<p>Other reported reactions seen less frequently in clinical trials included <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, sunburn, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>.</p>
<p><span class="Bold">Initial Therapy - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>In a clinical study in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic blood pressure ≥110 mmHg and systolic blood pressure ≥140 mmHg), the overall pattern of adverse reactions reported through 6 weeks of follow-up was similar in patients treated with Diovan HCT as initial therapy and in patients treated with valsartan as initial therapy. Comparing the groups treated with Diovan HCT (force-titrated to 320/25 mg) and valsartan (force-titrated to 320 mg), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was observed in 6% and 2% of patients, respectively. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was observed in 1% of those patients receiving Diovan HCT and 0% of patients receiving valsartan. There were no reported cases of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in either treatment group. Laboratory changes with Diovan HCT as initial therapy in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> were similar to those reported with Diovan HCT in patients with less severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> [<span class="Italics">see Clinical Studies (14.2) and Drug Interactions (7)</span>].</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> was significantly greater in the ACE inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129-patient trial limited to patients who had had <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> when they had previously received ACE inhibitors, the incidences of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in patients who received valsartan, hydrochlorothiazide, or lisinopril were 20%, 19%, 69% respectively (p &lt;0.001).</p>
<p>Other reported reactions seen less frequently in clinical trials included <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Other adverse reactions not listed above that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p><span class="Bold Italics">Body As A Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p><span class="Bold Italics">Digestive</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span></p>
<p><span class="Bold Italics">Hematologic</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span></p>
<p><span class="Bold Italics">Metabolic</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></p>
<p><span class="Bold Italics">Musculoskeletal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span></p>
<p><span class="Bold Italics">Nervous System/Psychiatric</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></p>
<p><span class="Bold Italics">Renal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Bold Italics">Skin</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
<p><span class="Bold Italics">Special Senses</span><span class="Bold Italics">: </span>transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span></p>
<p><span class="Bold">Clinical Laboratory Test Findings</span></p>
<p>In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Diovan HCT.</p>
<p><span class="Bold Italics">Creatinine/Blood Urea Nitrogen (BUN): </span>Minor elevations in creatinine and BUN occurred in 2% and 15% respectively, of patients taking Diovan HCT and 0.4% and 6% respectively, given placebo in controlled clinical trials</p>
<p><span class="Bold Italics">Hemoglobin and Hematocrit: </span>Greater than 20% decreases in hemoglobin and hematocrit were observed in less than 0.1% of Diovan HCT patients, compared with 0% in placebo-treated patients</p>
<p><span class="Bold Italics">Liver Function Tests: </span>Occasional elevations (greater than 150%) of liver chemistries occurred in Diovan HCT-treated patients</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: </span><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was observed in 0.1% of patients treated with Diovan HCT and 0.4% of patients treated with placebo</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p2"></a><a name="section-6.2"></a><p></p>
<h2>
6.2     Postmarketing Experience
</h2>
<p class="First">The following additional adverse reactions have been reported in valsartan or valsartan/hydrochlorothiazide postmarketing experience.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span><span class="Bold Italics">: </span>There are rare reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.  Some of these patients previously experienced <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with other drugs including ACE inhibitors.  Diovan HCT should not be re-administered to patients who have had <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold Italics">Digestive</span><span class="Bold Italics">: </span>Elevated liver enzymes and very rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Bold Italics">Renal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></p>
<p><span class="Bold Italics">Clinical Laboratory Tests</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></p>
<p><span class="Bold Italics">Dermatologic</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p>
<p><span class="Bold Italics">Vascular:</span>  <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></p>
<p><span class="Bold Italics">Nervous System: </span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers.</p>
<p><span class="Bold">Hydrochlorothiazide:</span></p>
<p>The following additional adverse reactions have been reported in post-marketing experience with hydrochlorothiazide:</p>
<p><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disorder</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">bone marrow failure</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">worsening of diabetes</span> control, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, blood <span class="product-label-link" type="condition" conceptid="4051221" conceptname="Increased lipid">lipids increased</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>.  </p>
<p>Pathological changes in the parathyroid gland of patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on prolonged thiazide therapy. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, further diagnostic evaluation is necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7     DRUG INTERACTIONS</span></h1>
<p class="First"><span class="Bold">Valsartan</span><span class="Bold">: </span>No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when valsartan was coadministered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.</p>
<p>Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.</p>
<p><span class="Italics">CYP</span><span class="Italics"></span><span class="Italics">450 Interactions</span><span class="Italics">: In vitro </span>metabolism studies indicate that CYP 450 mediated drug interactions between valsartan and co-administered drugs are unlikely because of the low extent of metabolism [<span class="Italics">see Clinical Pharmacology (12.3)</span>].</p>
<p><span class="Italics">Transporters:</span> The results from an <span class="Italics">in vitro</span> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and the hepatic efflux transporter MRP2. Coadministration of inhibitors of the uptake transporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</p>
<p><span class="Italics">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):  </span>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.  These effects are usually reversible.  Monitor renal function periodically in patients receiving valsartan and NSAID therapy. </p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including valsartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
<p><span class="Italics">Potassium: </span>Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients to increases in serum creatinine.  If co-medication is considered necessary, monitoring of serum potassium is advisable.</p>
<p><span class="Italics">Dual Blockade of the Renin-Angiotensin System (RAS): </span>Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patients on Diovan HCT and other agents that affect the RAS. </p>
<p>Do not coadminister aliskiren with Diovan HCT in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.  Avoid use of aliskiren with Diovan HCT in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;60 mL/min).
</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>When administered concurrently, the following drugs may interact with thiazide diuretics:</p>
<p><span class="Italics">Antidiabetic </span><span class="Italics">D</span><span class="Italics">rugs</span> (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics">Lithium</span> - Diuretic agents increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations before use of such preparations with Diovan HCT.  Monitoring of serum lithium concentrations is recommended during concurrent use.</p>
<p><span class="Italics">Nonsteroidal Anti-inflammatory Drugs</span> (NSAIDs and COX-2 selective inhibitors) - When Diovan HCT and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
<p><span class="Italics">Carbamazepine</span> – May lead to symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Italics">Ion exchange resins: </span><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Staggering</span> the dosage of hydrochlorothiazide and ion exchange resins (e.g., cholestyramine, colestipol) such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimize the interaction [<span class="Italics">see Clinical Pharmacology (12.3)</span>].</p>
<p><span class="Italics">Cyclosporine: </span>Concomitant treatment with cyclosporine may increase the risk of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>-type complications.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8     USE IN SPECIFIC POPULATIONS</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8p1"></a><a name="section-8.1"></a><p></p>
<h2>
8.1     Pregnancy
</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations.  Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue Diovan HCT as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.  Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.  Perform serial ultrasound examinations to assess the intra-amniotic environment.  If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue Diovan HCT, unless it is considered lifesaving for the mother.  Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.  Closely observe infants with histories of in utero exposure to Diovan HCT for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> [<span class="Italics">see Use in Specific Populations (8.4)</span>].</p>
<p><span class="Italics">Hydrochlorothiazide</span></p>
<p>Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma.   Hydrochlorothiazide, like other diuretics, can cause placental <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span>. It accumulates in the amniotic fluid, with reported concentrations up to 19 times higher than in umbilical vein plasma. Use of thiazides during pregnancy is associated with a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Since they do not prevent or alter the course of EPH (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>) <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">gestosis</span> (pre-<span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span>), these drugs should not be used to treat <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in pregnant women. The use of hydrochlorothiazide for other indications (e.g., heart disease) in pregnancy should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8p3"></a><a name="section-8.2"></a><p></p>
<h2>
8.3     Nursing Mothers
</h2>
<p class="First">It is not known whether valsartan is excreted in human milk. Valsartan was excreted into the milk of lactating rats; however, animal breast milk drug levels may not accurately reflect human breast milk levels. Hydrochlorothiazide is excreted in human breast milk. Because many drugs are excreted into human milk and because of the potential for adverse reactions in nursing infants from Diovan HCT, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8p4"></a><a name="section-8.3"></a><p></p>
<h2>
8.4     Pediatric Use
</h2>
<p class="First">Safety and effectiveness of Diovan HCT in pediatric patients have not been established.</p>
<p>Neonates with a history of in utero exposure to Diovan HCT:</p>
<p>If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion.  Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8p5"></a><a name="section-8.4"></a><p></p>
<h2>
8.5     Geriatric Use
</h2>
<p class="First">In the controlled clinical trials of Diovan HCT, 764 (17.5%) patients treated with valsartan-hydrochlorothiazide were ≥65 years and 118 (2.7%) were ≥75 years. No overall difference in the efficacy or safety of valsartan-hydrochlorothiazide was observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p6"></a><a name="section-8.5"></a><p></p>
<h2>
8.6     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Safety and effectiveness of Diovan HCT in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≤ 30 mL/min) have not been established. No dose adjustment is required in patients with mild (CrCl 60-90 mL/min) or moderate (CrCl 30-60) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p7"></a><a name="section-8.6"></a><p></p>
<h2>
8.7     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Valsartan</p>
<p>No dose adjustment is necessary for patients with mild-to-moderate liver disease. No dosing recommendations can be provided for patients with severe liver disease.    </p>
<p><span class="Italics Underline">Hydrochlorothiazide</span></p>
<p>Minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> in patients with impaired hepatic function or progressive liver disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">10     OVERDOSAGE</span></h1>
<p class="First"><span class="Bold">Valsartan – Hydrochlorothiazide</span><span class="Bold">: </span>Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have been reported. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted.</p>
<p>Valsartan is not removed from the plasma by dialysis.</p>
<p>The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The most common signs and symptoms observed in patients are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>In rats and marmosets, single oral doses of valsartan up to 1524 and 762 mg/kg in combination with hydrochlorothiazide at doses up to 476 and 238 mg/kg, respectively, were very well tolerated without any treatment-related effects. These no adverse effect doses in rats and marmosets, respectively, represent 46.5 and 23 times the maximum recommended human dose (MRHD) of valsartan and 188 and 113 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the rat and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in the marmoset at the highest dose (60 and 31 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis). (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10 g/kg in both mice and rats, which represents 2027 and 4054 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">11     DESCRIPTION</span></h1>
<p class="First">Diovan HCT (valsartan and hydrochlorothiazide, USP) is a combination of valsartan, an orally active, specific angiotensin II receptor blocker (ARB) acting on the AT<span class="Sub">1</span> receptor subtype, and hydrochlorothiazide, a diuretic.</p>
<p>Valsartan, a nonpeptide molecule, is chemically described as <span class="Italics">N</span>-(1-oxopentyl)-<span class="Italics">N</span>-[[2′-(1<span class="Italics">H</span>-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-Valine. Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">29</span>N<span class="Sub">5</span>O<span class="Sub">3</span>, its molecular weight is 435.5, and its structural formula is</p>
<p><img alt="Valsartan structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=diovan-hct-05.jpg"></p>
<p>Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water.</p>
<p>Hydrochlorothiazide USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in <span class="Italics">n</span>-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span>, its molecular weight is 297.73, and its structural formula is</p>
<p><img alt="Hydrochlorothiazide structural formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=diovan-hct-06.jpg"></p>
<p>Diovan HCT tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide, USP 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg, and 320/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12     CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
12.1     Mechanism of Action
</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT<span class="Sub">1</span> receptor about one 200th that of valsartan itself.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II) it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>
12.2     Pharmacodynamics
</h2>
<p class="First"><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan inhibits the pressor effect of angiotensin II infusions. An oral dose of 80 mg inhibits the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. No information on the effect of larger doses is available.</p>
<p>Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan; very little effect on serum potassium was observed.</p>
<p><span class="Bold">Hydrochlorothiazide</span>: After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
<p><span class="Bold">Drug Interactions</span></p>
<p><span class="Bold Underline">Hydrochlorothiazide:</span></p>
<p><span class="Italics">Alcohol, barbiturates, or narcotics: </span>Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Skeletal muscle relaxants: </span>Possible increased responsiveness to muscle relaxants such as curare derivatives.</p>
<p><span class="Italics">Digitalis glycosides: </span>Thiazide-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> may predispose the patient to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>
12.3     Pharmacokinetics
</h2>
<p class="First"><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan peak plasma concentration is reached 2 to 4 hours after dosing. Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours. Absolute bioavailability for the capsule formulation is about 25% (range 10%-35%). Food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<span class="Sub">max</span>) by about 50%. AUC and C<span class="Sub">max</span> values of valsartan increase approximately linearly with increasing dose over the clinical dosing range. Valsartan does not accumulate appreciably in plasma following repeated administration.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>The estimated absolute bioavailability of hydrochlorothiazide after oral administration is about 70%. Peak plasma hydrochlorothiazide concentrations (C<span class="Sub">max</span>) are reached within 2 to 5 hours after oral administration. There is no clinically significant effect of food on the bioavailability of hydrochlorothiazide. </p>
<p>Hydrochlorothiazide binds to albumin (40 to 70%) and distributes into erythrocytes. Following oral administration, plasma hydrochlorothiazide concentrations decline bi-exponentially, with a mean distribution half-life of about 2 hours and an elimination half-life of about 10 hours. </p>
<p><span class="Bold">Diovan HCT:  </span>Diovan HCT may be administered with or without food.</p>
<p><span class="Bold">Distribution</span></p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>The steady state volume of distribution of valsartan after intravenous administration is small (17 L), indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (95%), mainly serum albumin.</p>
<p><span class="Bold">Metabolism</span></p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan.  <span class="Italics">In vitro</span> metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan. Valsartan does not inhibit CYP 450 isozymes at clinically relevant concentrations. CYP 450 mediated drug interaction between valsartan and coadministered drugs are unlikely because of the low extent of metabolism.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Is not metabolized.</p>
<p><span class="Bold">Excretion</span></p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose). The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites.</p>
<p>Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.62 L/h (about 30% of total clearance).</p>
<p><span class="Bold">Hydrochlorothiazide:</span> About 70% of an orally administered dose of hydrochlorothiazide is eliminated in the urine as unchanged drug. </p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Bold Italics">Geriatric: </span>Exposure (measured by AUC) to valsartan is higher by 70% and the half-life is longer by 35% in the elderly than in the young. A limited amount of data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers. </p>
<p><span class="Bold Italics">Gender: </span>Pharmacokinetics of valsartan do not differ significantly between males and females.</p>
<p><span class="Bold Italics">Race: </span> Pharmacokinetic differences due to race have not been studied.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>: </span>There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Valsartan has not been studied in patients with severe impairment of renal function (creatinine clearance &lt;10 mL/min). Valsartan is not removed from the plasma by hemodialysis. </p>
<p>In a study in individuals with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, the mean elimination half-life of hydrochlorothiazide was doubled in individuals with mild/moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (30 &lt; CrCl &lt; 90 mL/min) and tripled in severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (≤ 30 mL/min), compared to individuals with normal renal function (CrCl &gt; 90 mL/min) [<span class="Italics">see Use in Specific Populations (8.6)</span>].</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>: </span> On average, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> have twice the exposure (measured by AUC values) to valsartan of healthy volunteers (matched by age, sex, and weight) <span class="Italics">[see Use in Specific Populations (8.7)].</span></p>
<p><span class="Bold">Drug Interactions</span></p>
<p><span class="Bold">Hydrochlorothiazide:</span></p>
<p><span class="Italics">Drugs that alter gastrointestinal motility: </span>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, pro-kinetic drugs may decrease the bioavailability of thiazide diuretics.</p>
<p><span class="Italics">Cholestyramine: </span>In a dedicated drug interaction study, administration of cholestyramine 2 hours before hydrochlorothiazide resulted in a 70% reduction in exposure to hydrochlorothiazide.  Further, administration of hydrochlorothiazide 2 hours before cholestyramine resulted in 35% reduction in exposure to hydrochlorothiazide. </p>
<p><span class="Italics">Antineoplastic agents (e.g., cyclophosphamide, methotrexate): </span>Concomitant use of thiazide diuretics may reduce renal excretion of cytotoxic agents and enhance their myelosuppressive effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13     NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First"><span class="Bold">Valsartan</span>-<span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>No carcinogenicity, mutagenicity, or fertility studies have been conducted with the combination of valsartan and hydrochlorothiazide. However, these studies have been conducted for valsartan as well as hydrochlorothiazide alone. Based on the preclinical safety and human pharmacokinetic studies, there is no indication of any adverse interaction between valsartan and hydrochlorothiazide.</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>There was no evidence of carcinogenicity when valsartan was administered in the diet to mice and rats for up to 2 years at doses up to 160 and 200 mg/kg/day, respectively. These doses in mice and rats are about 2.6 and 6 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p>Mutagenicity assays did not reveal any valsartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span><span class="Italics"></span>(Ames) and <span class="Italics">E. coli</span>; a gene mutation test with Chinese hamster V79 cells; a cytogenetic test with Chinese hamster ovary cells; and a rat micronucleus test.</p>
<p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is about 6 times the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic <span class="Italics">in vitro</span> in the Ames mutagenicity assay of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> Typhimurium </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or <span class="Italics">in vivo</span> in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained only in the <span class="Italics">in vitro</span> CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 mcgm/mL, and in the Aspergillus Nidulans non-disjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and 1.5 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>
13.3     Developmental Toxicity Studies
</h2>
<p class="First"><span class="Bold">Valsartan-Hydrochlorothiazide</span><span class="Bold">: </span>There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in mice, rats, or rabbits treated orally with valsartan at doses up to 600, 100, and 10 mg/kg/day, respectively, in combination with hydrochlorothiazide at doses up to 188, 31, and 3 mg/kg/day. These non-teratogenic doses in mice, rats and rabbits, respectively, represent 9, 3.5, and 0.5 times the MRHD of valsartan and 38, 13, and 2 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p>Fetotoxicity was observed in association with maternal toxicity in rats and rabbits at valsartan doses of ≥200 and 10 mg/kg/day, respectively, in combination with hydrochlorothiazide doses of ≥63 and 3 mg/kg/day. Fetotoxicity in rats was considered to be related to decreased fetal weights and included fetal variations of sternebrae, vertebrae, ribs and/or renal papillae. Fetotoxicity in rabbits included increased numbers of late resorptions with resultant increases in total resorptions, postimplantation losses, and decreased number of live fetuses. The no observed adverse effect doses in mice, rats and rabbits for valsartan were 600, 100, and 3 mg/kg/day, respectively, in combination with hydrochlorothiazide doses of 188, 31, and 1 mg/kg/day. These no adverse effect doses in mice, rats, and rabbits, respectively, represent 9, 3, and 0.18 times the MRHD of valsartan and 38, 13, and 0.5 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>No teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses up to 600 mg/kg/day and to pregnant rabbits at oral doses up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, and low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200, and 2 mg/kg/day in mice, rats, and rabbits represent 9, 6, and 0.1 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Under the auspices of the National Toxicology Program, pregnant mice and rats that received hydrochlorothiazide via gavage at doses up to 3000 and 1000 mg/kg/day, respectively, on gestation days 6 through 15 showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. These doses of hydrochlorothiazide in mice and rats represent 608 and 405 times, respectively, the MRHD on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1><span class="Bold">14     CLINICAL STUDIES</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>
14.1     <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</h2>
<p class="First"><span class="Bold">Valsartan</span>-<span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>In controlled clinical trials including over 7600 patients, 4372 patients were exposed to valsartan (80, 160, and 320 mg) and concomitant hydrochlorothiazide (12.5 and 25 mg). Two factorial trials compared various combinations of 80/12.5 mg, 80/25 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg, and 320/25 mg with their respective components and placebo. The combination of valsartan and hydrochlorothiazide resulted in additive placebo-adjusted decreases in systolic and diastolic blood pressure at trough of 14-21/8-11 mmHg at 80/12.5 mg to 320/25 mg, compared to 7-10/4-5 mmHg for valsartan 80 mg to 320 mg, and 5-11/2-5 mmHg for hydrochlorothiazide 12.5 mg to 25 mg alone.</p>
<p>Three other controlled trials investigated the addition of hydrochlorothiazide to patients who did not respond adequately to valsartan 80 mg to valsartan 320 mg, resulted in the additional lowering of systolic and diastolic blood pressure by approximately 4-12/2-5 mmHg.</p>
<p>The maximal antihypertensive effect was attained 4 weeks after the initiation of therapy, the first time point at which blood pressure was measured in these trials.</p>
<p>In long-term follow-up studies (without placebo control) the effect of the combination of valsartan and hydrochlorothiazide appeared to be maintained for up to 2 years. The antihypertensive effect is independent of age or gender. The overall response to the combination was similar for black and non-black patients.</p>
<p>There was essentially no change in heart rate in patients treated with the combination of valsartan and hydrochlorothiazide in controlled trials. </p>
<p>There are no trials of the Diovan HCT combination tablet demonstrating reductions in cardiovascular risk in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, but  the hydrochlorothiazide component and several ARBs, which are the same pharmacological class as the  valsartan component,  have demonstrated such benefits.</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>The antihypertensive effects of valsartan were demonstrated principally in 7 placebo-controlled, 4- to 12-week trials (1 in patients over 65) of dosages from 10 to 320 mg/day in patients with baseline diastolic blood pressures of 95-115. The studies allowed comparison of once-daily and twice-daily regimens of 160 mg/day; comparison of peak and trough effects; comparison (in pooled data) of response by gender, age, and race; and evaluation of incremental effects of hydrochlorothiazide.</p>
<p>Administration of valsartan to patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> results in a significant reduction of sitting, supine, and standing systolic and diastolic blood pressure, usually with little or no orthostatic change.</p>
<p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs at approximately 2 hours, and maximum reduction of blood pressure is achieved within 6 hours. The antihypertensive effect persists for 24 hours after dosing, but there is a decrease from peak effect at lower doses (40 mg) presumably reflecting loss of inhibition of angiotensin II. At higher doses, however (160 mg), there is little difference in peak and trough effect. During repeated dosing, the reduction in blood pressure with any dose is substantially present within 2 weeks, and maximal reduction is generally attained after 4 weeks. In long-term follow-up studies (without placebo control) the effect of valsartan appeared to be maintained for up to 2 years. The antihypertensive effect is independent of age, gender or race. The latter finding regarding race is based on pooled data and should be viewed with caution, because antihypertensive drugs that affect the renin-angiotensin system (that is, ACE inhibitors and angiotensin II blockers) have generally been found to be less effective in low-renin hypertensives (frequently blacks) than in high-renin hypertensives (frequently whites). In pooled, randomized, controlled trials of Diovan that included a total of 140 blacks and 830 whites, valsartan and an ACE-inhibitor control were generally at least as effective in blacks as whites. The explanation for this difference from previous findings is unclear.</p>
<p>Abrupt withdrawal of valsartan has not been associated with a rapid increase in blood pressure.</p>
<p>The 7 studies of valsartan monotherapy included over 2000 patients randomized to various doses of valsartan and about 800 patients randomized to placebo. Doses below 80 mg were not consistently distinguished from those of placebo at trough, but doses of 80, 160 and 320 mg produced dose-related decreases in systolic and diastolic blood pressure, with the difference from placebo of approximately 6-9/3-5 mmHg at 80-160 mg and 9/6 mmHg at 320 mg.</p>
<p>Patients with an inadequate response to 80 mg once daily were titrated to either 160 mg once daily or 80 mg twice daily, which resulted in a comparable response in both groups.</p>
<p>In another 4-week study, 1876 patients randomized to valsartan 320 mg once daily had an incremental blood pressure reduction 3/1 mmHg lower than did 1900 patients randomized to valsartan 160 mg once daily.</p>
<p>In controlled trials, the antihypertensive effect of once daily valsartan 80 mg was similar to that of once daily enalapril 20 mg or once daily lisinopril 10 mg.</p>
<p>There was essentially no change in heart rate in valsartan-treated patients in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>
14.2     Initial Therapy - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</h2>
<p class="First">The safety and efficacy of Diovan HCT as initial therapy for patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (defined as a sitting diastolic blood pressure ≥110 mmHg and systolic blood pressure ≥140 mmHg off all antihypertensive therapy) was studied in a 6-week multicenter, randomized, double-blind study. Patients were randomized to either Diovan HCT (valsartan and hydrochlorothiazide 160/12.5 mg once daily) or to valsartan (160 mg once daily) and followed for blood pressure response. Patients were force-titrated at 2-week intervals. Patients on combination therapy were subsequently titrated to 160/25 mg followed by 320/25 mg valsartan/hydrochlorothiazide. Patients on monotherapy were subsequently titrated to 320 mg valsartan followed by a titration to 320 mg valsartan to maintain the blind. </p>
<p>The study randomized 608 patients, including 261 (43%) females, 147 (24%) blacks, and 75 (12%) ≥65 years of age. The mean blood pressure at baseline for the total population was 168/112 mmHg. The mean age was 52 years. After 4 weeks of therapy, reductions in systolic and diastolic blood pressure were 9/5 mmHg greater in the group treated with Diovan HCT compared to valsartan. Similar trends were seen when the patients were grouped according to gender, race, or age. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
16     HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Diovan HCT (valsartan and hydrochlorothiazide, USP) is available as non-scored tablets containing valsartan/hydrochlorothiazide 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg, and 320/25 mg. Strengths are available as follows.</p>
<p><span class="Bold">80/12.5</span><span class="Bold">mg Tablet</span> - Light orange, ovaloid, with slightly convex faces debossed CG on 1 side and HGH on the other side.</p>
<p>
     
Bottles of 90
     
NDC 0078-0314-34</p>
<p>
     
Bottles of 14,000
     
NDC 0078-0314-33</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
     
NDC 0078-0314-06</p>
<p>
     
Box of 100 (strips of 10)</p>
<p><span class="Bold">160/12.5</span><span class="Bold">mg Tablet</span> - Dark red, ovaloid, with slightly convex faces debossed CG on 1 side and HHH on the other side.</p>
<p>
     
Bottles of 90
     
NDC 0078-0315-34</p>
<p>
     
Bottles of 7,000
     
NDC 0078-0315-17</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
     
NDC 0078-0315-06</p>
<p>
     
Box of 100 (strips of 10)</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
     
NDC 0078-0315-15</p>
<p><span class="Bold">160/25 mg</span><span class="Bold">Tablet</span> - Brown orange, ovaloid, with slightly convex faces debossed NVR on 1 side and HXH on the other side.</p>
<p>
     
Bottles of 90
     
NDC 0078-0383-34</p>
<p>
     
Bottles of 7,000
     
NDC 0078-0383-17</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
     
NDC 0078-0383-06</p>
<p>
     
Box of 100 (strips of 10)</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
     
NDC 0078-0383-15</p>
<p><span class="Bold">320/12.5</span><span class="Bold">mg Tablet</span> - Pink, ovaloid, with beveled edge, debossed NVR on 1 side and HIL on the other side.</p>
<p>
     
Bottles of 90
     
NDC 0078-0471-34</p>
<p>
     
Bottles of 3,500
     
NDC 0078-0471-11</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
     
NDC 0078-0471-06</p>
<p>		     
Box of 100 (strips of 10)</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
     
NDC 0078-0471-15</p>
<p><span class="Bold">320/25 mg</span><span class="Bold">Tablet</span> - Yellow, ovaloid, with beveled edge, debossed NVR on 1 side and CTI on the other side.</p>
<p>
     
Bottles of 90
     
NDC 0078-0472-34</p>
<p>
     
Bottles of 3,500		     
NDC 0078-0472-11</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
     
NDC 0078-0472-06</p>
<p>
     
Box of 100 (strips of 10)</p>
<p>
     
Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
     
NDC 0078-0472-15</p>
<p>Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature].</p>
<p>Protect from moisture.</p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>
17     PATIENT COUNSELING INFORMATION
</h1>
<p class="First"><span class="Bold">Information for Patients</span></p>
<p><span class="Bold Italics">Pregnancy:  </span>Female patients of childbearing age should be told about the consequences of exposure to Diovan HCT during pregnancy.  Discuss treatment options with women planning to become pregnant.  Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
<p><span class="Bold Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: </span>A patient receiving Diovan HCT should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, Diovan HCT should be discontinued until the physician has been consulted.</p>
<p>All patients should be cautioned that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold Italics">Potassium Supplements</span><span class="Bold Italics">: </span>A patient receiving Diovan HCT should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.</p>
<p>T2012-186<br>October 2012</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling </span></p>
<p><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">DIOVAN</span><span class="Bold">HCT (DYE’</span><span class="Bold">-o</span><span class="Bold">-van HCT)</span></p>
<p><span class="Bold">(valsartan and hydrochlorothiazide) </span></p>
<p><span class="Bold">Tablets</span></p>
<p>Read the Patient Information that comes with DIOVAN HCT before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition and treatment. If you have any questions about DIOVAN HCT, ask your doctor or pharmacist.</p>
<table>
<colgroup><col width="934"></colgroup>
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule Toprule">
<span class="Bold">What is the most important information I should know about DIOVAN HCT?</span><br>Diovan HCT can cause harm or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. If you get pregnant while taking Diovan HCT, tell your doctor right away.</td></tr></tbody>
</table>
<p><span class="Bold">What is DIOVAN</span><span class="Bold">HCT?</span></p>
<p>DIOVAN HCT contains 2 prescription medicines:</p>
<ol class="Arabic">
<li>valsartan, an angiotensin receptor blocker (ARB)</li>
<li>hydrochlorothiazide (HCTZ), a water pill (diuretic)</li>
</ol>
<p>DIOVAN HCT may be used to lower high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) in adults-</p>
<ul class="Disc">
<li>when 1 medicine to lower your high blood pressure is not enough.</li>
<li>as the first medicine to lower high blood pressure if your doctor decides you are likely to need more than 1 medicine.</li>
</ul>
<p>DIOVAN HCT has not been studied in children under 18 years of age.</p>
<p><span class="Bold">Who should not take DIOVAN</span><span class="Bold">HCT?</span></p>
<p><span class="Bold">Do not take DIOVAN</span><span class="Bold">HCT if you:</span></p>
<ul class="Disc">
<li>
<span class="Bold">are allergic to any of the ingredients in DIOVAN HCT.</span> See the end of this leaflet for a complete list of ingredients in DIOVAN HCT.</li>
<li>make less urine due to kidney problems.</li>
<li>are allergic to medicines that contain sulfonamides.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking DIOVAN</span><span class="Bold">HCT?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions including if you:</span></p>
<ul class="Disc">
<li>
<span class="Bold">are pregnant or plan to become pregnant.</span> See “What is the most important information I should know about DIOVAN HCT??</li>
<li>
<span class="Bold">are breastfeeding.</span> DIOVAN HCT passes into breast milk. You should choose either to take DIOVAN HCT or breastfeed, but not both.</li>
<li><span class="Bold">have liver problems</span></li>
<li><span class="Bold">have kidney problems</span></li>
<li><span class="Bold">have or had <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span> </span></li>
<li><span class="Bold">have Lupus</span></li>
<li>
<span class="Bold">have low levels of potassium </span>(with or without symptoms such as <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, abnormal heart rhythm) or magnesium in your blood </li>
<li>
<span class="Bold">have high levels of calcium in your blood </span>(with or without symptoms such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, frequent urination, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>). </li>
<li><span class="Bold">have high levels of uric acid in the blood. </span></li>
<li><span class="Bold">have ever had a reaction called <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, to another blood pressure medication. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> causes <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, throat and may cause <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>. </span></li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span> including prescription and nonprescription medicines, vitamins and herbal supplements. Some of your other medicines and DIOVAN HCT could affect each other, causing serious side effects. Especially, tell your doctor if you take:</p>
<ul class="Disc">
<li>other medicines for high blood pressure or a heart problem</li>
<li>water pills (diuretics)</li>
<li>potassium supplements. Your doctor may check the amount of potassium in your blood periodically. </li>
<li>a salt substitute. Your doctor may check the amount of potassium in your blood periodically. </li>
<li>antidiabetic medicines including insulin</li>
<li>narcotic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines</li>
<li>sleeping pills</li>
<li>lithium, a medicine used in some types of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (Eskalith<span class="Sup">®</span>, Lithobid<span class="Sup">®</span>, Lithium Carbonate, Lithium Citrate)</li>
<li>aspirin or other medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), like ibuprofen or naproxen </li>
<li>digoxin or other digitalis glycosides (a heart medicine)</li>
<li>muscle relaxants (medicines used during operations)</li>
<li>certain cancer medicines, like cyclophosphamide or methotrexate</li>
<li>certain antibiotics (rifamycin group), a drug used to protect against <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span> (cyclosporin) or an antiretroviral drug used to treat HIV/AIDS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (ritonavir). These drugs may increase the effect of valsartan.</li>
</ul>
<p>Ask your doctor if you are not sure if you are taking 1 of these medicines.</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show to your doctor and pharmacist when a new medicine is prescribed. Talk to your doctor or pharmacist before you start taking any new medicine. Your doctor or pharmacist will know what medicines are safe to take together.</p>
<p><span class="Bold">How should I take DIOVAN</span><span class="Bold">HCT?</span></p>
<ul class="Disc">
<li>Take DIOVAN HCT exactly as prescribed by your doctor. Your doctor may change your dose if needed.</li>
<li>Take DIOVAN HCT once each day.</li>
<li>DIOVAN HCT can be taken with or without food.</li>
<li>If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Just take the next dose at your regular time.</li>
<li>If you take too much DIOVAN HCT, call your doctor or Poison Control Center, or go to the nearest hospital emergency room.</li>
</ul>
<p><span class="Bold">What should I avoid while taking DIOVAN HCT?</span></p>
<p>You should not take DIOVAN HCT during pregnancy. See “What is the most important information I should know about DIOVAN HCT??</p>
<p><span class="Bold">What are the possible side effects of DIOVAN</span><span class="Bold">HCT?</span></p>
<p><span class="Bold">DIOVAN</span><span class="Bold">HCT may cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Harm to an unborn baby causing injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>See “What is the most important information I should know about DIOVAN HCT??</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>).</span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> is most likely to happen if you:<ul class="Circle">
<li>take water pills </li>
<li>are on a low salt diet</li>
<li>get dialysis treatments</li>
<li>have heart problems</li>
<li>get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>drink alcohol</li>
</ul>
</li>
</ul>
<p>Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy. Call your doctor right away.</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></span><span class="Bold">. </span>People with and without <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> problems or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who take DIOVAN HCT may get <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</li>
<li>
<span class="Bold">Worsening of Lupus</span><span class="Bold">. </span>Hydrochlorothiazide, 1 of the medicines in DIOVAN HCT may cause Lupus to become active or worse.</li>
<li>
<span class="Bold">Fluid and electrolyte (salt) problems</span><span class="Bold">. </span>Tell your doctor about any of the following signs and symptoms of fluid and electrolyte problems:</li>
</ul>
<table>
<colgroup>
<col width="254">
<col width="247">
<col width="234">
</colgroup>
<tbody class="Headless"><tr class="First Last">
<td><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></li>
<li>lack of energy (<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargic</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
</ul></td>
<td><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span></li>
</ul></td>
<td><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span></li>
<li>very low urine output</li>
<li>fast heartbeat</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul></td>
</tr></tbody>
</table>
<ul class="Disc">
<li>
<span class="Bold">K</span><span class="Bold">idney problems. </span>Kidney problems may become worse in people that already have kidney disease. Some people will have changes on blood tests for kidney function and may need a lower dose of DIOVAN HCT. Call your doctor if you get <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands, or unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, your doctor should check your kidney function before prescribing DIOVAN HCT.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>.</span> Call your doctor right away if you have an unusual <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</li>
<li>
<span class="Bold">Eye Problems.</span>One of the medicines in DIOVAN HCT can cause eye problems that may lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. Symptoms of eye problems can happen within hours to weeks of starting DIOVAN HCT. Tell your doctor right away if you have:<ul class="Disc">
<li>decrease in vision</li>
<li><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span></li>
</ul>
</li>
</ul>
<p>Other side effects were generally mild and brief. They generally have not caused patients to stop taking DIOVAN HCT.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of DIOVAN HCT. For a complete list, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How do I store DIOVAN</span><span class="Bold">HCT?</span></p>
<ul class="Disc">
<li>Store DIOVAN HCT tablets at room temperature between 59<span class="Sup">o</span>F to 86<span class="Sup">o</span>F (15<span class="Sup">o</span>C to 30<span class="Sup">o</span>C).</li>
<li>Keep DIOVAN HCT in a closed container in a dry place.</li>
</ul>
<p><span class="Bold">Keep DIOVAN</span><span class="Bold">HCT and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about DIOVAN</span><span class="Bold">HCT</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use DIOVAN HCT for a condition for which it was not prescribed. Do not give DIOVAN HCT to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about DIOVAN HCT. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about DIOVAN HCT that is written for health professionals. For more information about DIOVAN HCT, go to www.DIOVAN.com or call 1-866-404-6359.</p>
<p><span class="Bold">What are the ingredients in DIOVAN</span><span class="Bold">HCT?</span></p>
<p>Active ingredients: Valsartan and hydrochlorothiazide</p>
<p>Inactive ingredients: colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide.</p>
<p><span class="Bold">What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?</span></p>
<p>Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. DIOVAN HCT can help your blood vessels relax and reduce the amount of water in your body so your blood pressure is lower. Medicines that lower blood pressure lower your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</p>
<p>High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems.</p>
<p>Eskalith<span class="Sup">® </span>and Lithobid<span class="Sup">®</span> are registered trademarks of Noven Pharmaceuticals, Inc.</p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey 07936</p>
<p>© Novartis</p>
<p><br>T2012-187<br>October 2012 </p>
<p></p>
<p>And Relabeled By:</p>
<p>Dispensing Solutions Inc.<br>3000 West Warner Ave<br>Santa Ana, CA 92704<br>United States</p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1><span><span class="Bold">PRINCIPAL DISPLAY PANEL﻿</span></span></h1>
<p class="First">NDC 68258-6972-03</p>
<p><img alt="NDC 68258-6972-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=NDC%2068258-6972-03------NOVARTIS.jpg"></p>
<p></p>
<p>NDC 68258-6973-03</p>
<p><img alt="NDC 68258-6973-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bbdcc66-c8c0-4710-a447-d12cc78b5aa8&amp;name=NDC%2068258-6973-03------NORVATIS.jpg"></p>
<p></p>
<p></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIOVAN HCT 		
					</strong><br><span class="contentTableReg">valsartan and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68258-6972(NDC:0078-0315)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">160 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (Dark red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CG;HHH</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68258-6972-3</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020818</td>
<td class="formItem">03/06/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIOVAN HCT 		
					</strong><br><span class="contentTableReg">valsartan and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68258-6973(NDC:0078-0383)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">160 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Brown orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;HXH</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68258-6973-3</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020818</td>
<td class="formItem">03/06/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dispensing Solutions, Inc.
							(066070785)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PSS World Medical, Inc. (101822682)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dispensing Solutions, Inc.</td>
<td class="formItem"></td>
<td class="formItem">066070785</td>
<td class="formItem">relabel(68258-6972), repack(68258-6972)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1b1be459-a727-487a-aefd-f3c3757b6cc9</div>
<div>Set id: 1bbdcc66-c8c0-4710-a447-d12cc78b5aa8</div>
<div>Version: 1</div>
<div>Effective Time: 20131003</div>
</div>
</div> <div class="DistributorName">Dispensing Solutions, Inc.</div></p>
</body></html>
